Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (14241)	11/19/2004 10:14:18 PM
From: Miljenko Zuanic	of 52153

Fpgs, We are talking about certain level of the EGFR expression. Threshold when one can argue that cancer growth is in one way driven by EGF. However, who can tell that EGFr level expression below 1% is irrelevant or not sufficient to facilitate or direct cancer growth and spread. Second, are we talking about EGFr expression at primary site or metastatic one? IMCL have problem with this. Over-expression at primary site is not guaranty that receptor level is higher at metastatic. And, drug action is mostly for metastases, not primary cancer. Anyway, EGFr level is less important for survival than for RR. I still think that Irresa and Tarceva have additional activity than simple Anti-egfr. Have no idea what they are! Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next